AstraZeneca Plc (NASDAQ: AZN) released results from the 24-week and long-term extension (LTE) period of the ALPHA Phase 3 trial of danicopan as an add-on to C5 inhibitor therapy...
AstraZeneca (NASDAQ:AZN) announced the termination of two significant Phase III trials, STABILIZE-CKD and DIALIZE-Outcomes, from its CRYSTALIZE programme. The decision was made due...
VANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a leader in generative AI antibody discovery, today announced a collaboration with...
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in...
AstraZeneca (NASDAQ:AZN) plc has announced the discontinuation of its Phase III STABILIZE-CKD and DIALIZE-Outcomes trials, which were investigating treatments for chronic kidney...
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due...
New York, USA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight | Key...
LONDON - Barclays (LON:BARC) has made a series of recalibrations to its price targets on a range of FTSE-listed stocks, reflecting a mix of optimism and caution in its latest...